Literature DB >> 27253466

Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection.

Masao Nakajima1, Tomio Ueno, Nobuaki Suzuki, Hiroto Matsui, Yoshitaro Shindo, Kazuhiko Sakamoto, Yoshihiro Tokuhisa, Yukio Tokumitsu, Shigeru Takeda, Shigefumi Yoshino, Shoichi Hazama, Hiroaki Nagano.   

Abstract

Few reports exist regarding surgical resection of metachronous lung metastases (MLM) from pancreatic ductal adenocarcinoma (PDA) after curative resection. To elucidate the indications for surgical resection of MLM and long-term survival, we analyzed Japanese case reports of MLM from PDA. Between 1983 and 2014, 17 Japanese case reports concerning surgical resection of MLM from PDA were published. We determined long-term survival in 16 patients (considering the published data of 15 patients and 1 of our own) by using a questionnaire survey and analyzing the relationships between background factors and long-term survival. In 16 patients with long-term survival, 4 patients were still alive without recurrence. The remaining 12 patients died of disease after recurrence. The median survival after the initial lobectomy was 37 months and the 3- and 5-year survival for all patients after lobectomy was 50% and 41%, respectively. Fourteen patients had a disease-free interval after initial resection of the primary pancreatic tumor of >20 months. These patients had a longer median survival period after lobectomy (46 vs. 25.5 mo, P=0.19). Seven patients had MLM of <16 mm. These patients had a statistically longer overall survival after lobectomy (83 vs. 16 mo, P=0.04). Three of 4 patients with primary stage I tumors were still alive without recurrence. We found that the conventional criteria for surgical resection of MLM from PDA (first disease-free interval of >20 mo with no other metastatic lesions) were appropriate. In addition, it is possible that MLM of <16 mm or primary stage I tumors are novel criteria.

Entities:  

Mesh:

Year:  2017        PMID: 27253466     DOI: 10.1097/MCG.0000000000000551

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

Review 1.  Oligometastatic Disease in Pancreatic Cancer - How to Proceed?

Authors:  Bernhard W Renz; Stefan Boeck; Falk Roeder; Christoph Trumm; Volker Heinemann; Jens Werner
Journal:  Visc Med       Date:  2017-02-10

2.  Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma.

Authors:  Mamoru Miyasaka; Takehiro Noji; Kazuto Ohtaka; Ryohei Chiba; Shoki Sato; Yasuhito Shoji; Ryunosuke Hase; Tatsunosuke Ichimura; Satoshi Hirano; Naoto Senmaru
Journal:  Clin J Gastroenterol       Date:  2017-10-16

Review 3.  Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.

Authors:  Martin Lovecek; Pavel Skalicky; Josef Chudacek; Marek Szkorupa; Hana Svebisova; Radmila Lemstrova; Jiri Ehrmann; Bohuslav Melichar; Tharani Yogeswara; Dusan Klos; Radek Vrba; Roman Havlik; Beatrice Mohelnikova-Duchonova
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

4.  Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study.

Authors:  Taro Mashiko; Akira Nakano; Yoshihito Masuoka; Seiichiro Yamamoto; Soji Ozawa; Toshio Nakagohri
Journal:  BMC Surg       Date:  2021-05-05       Impact factor: 2.102

5.  Metastatic pulmonary adenocarcinoma after 20 years of primary pancreatic adenocarcinoma resection: A case report and literature review.

Authors:  Osama N Dukmak; Almotazbellah Zeer; Mohammad Eid Al Mohtasib; Yousef Abu Asbeh
Journal:  Ann Med Surg (Lond)       Date:  2022-07-13

Review 6.  Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review.

Authors:  Florentine E F Timmer; Bart Geboers; Sanne Nieuwenhuizen; Evelien A C Schouten; Madelon Dijkstra; Jan J J de Vries; M Petrousjka van den Tol; Martijn R Meijerink; Hester J Scheffer
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.